Remove Financial Analysis Remove Pharmaceutical Remove Treasury
article thumbnail

5 Excel-heavy Pain Points still Dragging down finance teams in 2025

The Finance Weekly

A finance director at a large niche pharmaceutical company told us: “We have a lot of manual processes and inputting and that type of stuff which I am trying to get away from. All involving Excel data manipulation. One company we spoke to–a $110M equipment leasing firm–has been looking for a way out of this Excel mess for three years.

article thumbnail

Return on Equity, Earnings Yield and Market Efficiency: Back to Basics!

Musings on Markets

Carrying this through to the real world, you should not be surprised to see technology and pharmaceutical companies, the two biggest spenders on R&D, report much higher accounting returns than they are actually earning on their investments.

article thumbnail

5 Excel-heavy Pain Points still Dragging down finance teams in 2024

The Finance Weekly

A finance director at a large niche pharmaceutical company told us: “We have a lot of manual processes and inputting and that type of stuff which I am trying to get away from. All involving Excel data manipulation. One company we spoke to–a $110M equipment leasing firm–has been looking for a way out of this Excel hell for three years.